FDA Rejects Insys Therapeutics' New Drug Application

The FDA giveth and the FDA taketh away. On July 27, 2018, Insys Therapeutics (INSY) announced that the U.S. Food and Drug Administration declined to approve the company’s New Drug Application for Subsys, an opioid-based painkiller, on the grounds that it was potentially unsafe.

News of the denial on Friday sent Insys shares sliding by 9% to $6.62. For the last several years, Insys shares have been on the decline, due in large part to the company’s ongoing legal issues.

In 2016, seven Insys executives were arrested for conspiring to bride medical staff in several states to prescribe medication. Then, last year, INSYS founder John Kapoor was arrested in Arizona and charged with RICO conspiracy, conspiracy to commit wire fraud, and conspiracy to violate the Anti-Kickback Law for his efforts to secure prescriptions of Subsys.

Additionally, the company was sued earlier this year by the state of New York for deceptively promoting Subsys. Specifically, the state claimed that the company was engaging in a pattern of deceptive behavior by downplaying the risks of addiction by using Subsys, lying to healthcare providers to bypass the authorization process, and for bribing doctors to prescribe the medication. The suit is still ongoing.

Considering these legal issues, and the fact that an advisory committee in May recommended against approving the drug, it is less than surprising that the FDA denied approval to Subsys. In a statement, Insys senior vice president of regulatory affairs, Steve Sherman, tried to put on a good face in light of the potentially devasting news.

“Given the attributes of our proprietary buprenorphine formulation for sublingual delivery, we continue to believe that this drug-device combination could bring value to the management of pain and will assess the next steps in the context of the company’s overall mission,” said Sherman

Despite the disappointing news for investors, there are still at least three analysts that give Insys a Buy Rating, according to NASDAQ. Even after the company gets poor news on its drugs, investors seem to keep giving the company the benefit of the doubt. The stock tumbled in the summer of 2017 when its drug study didn’t go as planned and continued to fall until Insys executives kept talking up its pipeline giving some investors hope for a turnaround.

William Sumner

William Sumner

William Sumner is a freelance writer specializing in the legal cannabis industry. You can follow William on Twitter @W_Sumner or on Medium.


Leave a Reply

Your email address will not be published. Required fields are marked *


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 1 day

RT : The State of Cannabis SPACs was recorded on April 13, 2021. If you want to learn everything about SPACs in the cannabis i…

@GreenMarketRpt – 1 day

Not sure if you missed some news this week? Here’s a quick recap in #Psychedellux…

Back to Top

You have Successfully Subscribed!